Safety monitoring of an antibody treatment for childhood neuroblastoma

This is a long-term safety registry — essentially a careful tracking system — for children with high-risk neuroblastoma receiving dinutuximab beta, a monoclonal antibody designed to target cancer cells. Researchers want to monitor how well the medication works, how much pain it helps relieve, and what side effects patients experience over many years. This information will help doctors better understand the long-term benefits and risks of the treatment.

Neuroblastoma is a serious cancer that affects young children and often spreads throughout the body. Although newer treatments like this medication have shown promise, doctors need to understand how safe and effective it really is over a long period of time, especially regarding nerve damage, vision problems, and heart-related side effects.